{"entity":{"id":"nct03926624","kind":"trial","name":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","aka":[],"tldr":"A phase 3 trial of DFP-10917 run by Delta-Fly Pharma, Inc., terminated.","summary":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage is a phase 3 interventional study registered as NCT03926624 by Delta-Fly Pharma, Inc., with 167 participants enrolled, started 2019-11-22. Conditions recorded: Leukemia, Myeloid, Acute. Interventions recorded: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax and Cladribine.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03926624","url":"https://clinicaltrials.gov/study/NCT03926624"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["dfp-10917"],"companies":["delta-fly-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03926624","phase":"3","setting":"Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage","sponsor":"Delta-Fly Pharma, Inc.","enrolled":167,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03926624/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"dfp-10917","kind":"drug","name":"DFP-10917","route":"/drugs/dfp-10917/"}],"company":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/"}]}}